<DOC>
	<DOCNO>NCT00001409</DOCNO>
	<brief_summary>Certain patient enrol NIH protocol 94-I-0206 Clinical Center may eligible participate one follow new option : - Donor/recipient extension phase - Both recipient ( HIV-infected twin ) donor ( non-infected twin ) participate extension CD4-zeta gene therapy study . It evaluate safety activity infuse gene-modified CD4+ cell well modify CD8+ cell . - Corticosteroid administration - A corticosteroid , prednisone , hydrocortisone prednisolone , add interleukin-2 ( IL-2 ) regimen prevent treat side effect IL-2 fever flu-like symptom . - Extended follow-up - A intensive follow-up schedule patient substantial number lymphocytes harbor CD4-zeta gene . Every 3 month , participant blood test specialize test CD4 count , HIV-1 viral load number circulate cell contain CD4-zeta gene every 3 month &gt; frequency follow-up visit may reduce time go . - IL-2 continuation - Participants continue receive periodic treatment IL-2 see long genetically modify cell persist bloodstream evaluate long-term response IL-2 . - Home treatment interleukin-2 - Participants may receive future IL-2 treatment cycle home . Home treatment involve less frequent data safety monitoring medical evaluation Clinical Center except begin cycle .</brief_summary>
	<brief_title>Genetically Modified Lymphocytes Treat HIV-Infected Identical Twins - Study Modifications</brief_title>
	<detailed_description>Open-label , comparative , sequentially randomize treatment genetically unmodified modify ex vivo-expanded T-lymphocytes patient HIV infection posse seronegative syngeneic twin . Genetic modification consist introduction gene HLA-unrestricted `` universal '' receptor specific gp120 HIV envelope protein . Treatment divide Periods I II .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>INCLUSION CRITERIA : An identical twin pair , one seropositive HIV , twin seronegative , standard ELISA , PCR , Western blot test . Patients whose CD4+ count le 500/mm ( 3 ) entry must FDAapproved expandedaccess antiretroviral agent ( ) least 2 month . Patients Kaposi 's sarcoma eligible study , must receive systemic therapy KS within 4 week prior entry . The diagnosis KS must confirm biopsy . Anticipated survival great 6 month Karnofsky Performance Status great equal 60 % . Males females 18 year age old . Every effort make include gender . Free serious psychological emotional illness able provide write informed consent . EXCLUSION CRITERIA RECIPIENT : Lymphoma . Unwillingness comply current NIH Clinical Center guideline concern appropriate notification current sexual partner individual regard HIV positive serostatus risk transmission HIV infection . Recent history substance abuse unless evidence provide ongoing therapeutic intervention ( i.e . medical therapy counseling ) control abuse . Pregnancy entry unwillingness practice barrier birth control abstinence study . EXCLUSION CRITERIA DONOR : Untreated inadequately treated medical condition ( e.g. , cardiopulmonary disease , acute infection ) , judgement Principal Investigator , preclude apheresis . Serologic positivity Epstein Barr virus , Cytomegalovirus , Hepatitis B Hepatitis C recipient twin test seronegative correspond virus .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>AIDS</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>T Cell Universal Receptor</keyword>
	<keyword>Ex Vivo Activation</keyword>
</DOC>